Publications | Lucence 2/8

top of page

Publications

Filter by:

Targeted gene panel sequencing of liquid and tissue biopsies reveals actionable genomic alterations in Ghanaian metastatic breast cancer cases

Publications

1 Nov 2024

Targeted gene panel sequencing of liquid and tissue biopsies reveals actionable genomic alterations in Ghanaian metastatic breast cancer cases

Targeted gene panel sequencing of liquid and tissue biopsies reveals actionable genomic alterations in Ghanaian metastatic breast cancer cases

LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study

Publications

1 Jul 2024

LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study

LiquidHALLMARK detects more tissue-confirmed guideline-recommended biomarkers than Guardant360 for lung cancer: a prospective multicenter study

Multi-cancer early detection (MCED) in circulating tumor DNA (ctDNA) using an ultrasensitive mutation-based amplicon next-generation sequencing (NGS) assay.

Publications

29 May 2024

Multi-cancer early detection (MCED) in circulating tumor DNA (ctDNA) using an ultrasensitive mutation-based amplicon next-generation sequencing (NGS) assay.

Multi-cancer early detection (MCED) in circulating tumor DNA (ctDNA) using an ultrasensitive mutation-based amplicon next-generation sequencing (NGS) assay.

Association between CH mutation in TET2 and solid cancer in elderly Asian women.

Publications

29 May 2024

Association between CH mutation in TET2 and solid cancer in elderly Asian women.

Association between CH mutation in TET2 and solid cancer in elderly Asian women.

Utility of an amplicon-based ctDNA platform for advanced cholangiocarcinomas (CCA) in Asia.

Publications

29 May 2024

Utility of an amplicon-based ctDNA platform for advanced cholangiocarcinomas (CCA) in Asia.

Utility of an amplicon-based ctDNA platform for advanced cholangiocarcinomas (CCA) in Asia.

The Emerging Role of ctRNA in Liquid Biopsy - Insights From Two Clinical Trials in Oncogene-Driven Non-Small Cell Lung Cancer

Publications

13 May 2024

The Emerging Role of ctRNA in Liquid Biopsy - Insights From Two Clinical Trials in Oncogene-Driven Non-Small Cell Lung Cancer

The Emerging Role of ctRNA in Liquid Biopsy - Insights From Two Clinical Trials in Oncogene-Driven Non-Small Cell Lung Cancer

Real-world experience of an Asian pan-cancer combined DNA/RNA next generation sequencing (NGS) tissue biopsy assay

Publications

22 Mar 2024

Real-world experience of an Asian pan-cancer combined DNA/RNA next generation sequencing (NGS) tissue biopsy assay

Real-world experience of an Asian pan-cancer combined DNA/RNA next generation sequencing (NGS) tissue biopsy assay

Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay

Publications

1 Nov 2023

Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay

Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay

Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer

Publications

10 Sept 2023

Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer

Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer

1

/

8

bottom of page